

Speaker biographies

Robert Peter Gale

Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK



Robert Peter Gale was born in New York in 1945, received his AB with high honors in biology and chemistry from Hobart College in 1966, MD from the State University of New York at Buffalo in 1970 and PhD in microbiology and immunology from the University of California, Los Angeles (UCLA) in 1976). His postgraduate training was at UCLA 1970–74. 1983–4 he was the Meyerhoff Visiting Scholar at the Weizmann Institute of Science in molecular biology.

From 1973–1993, Gale was on the faculty of the UCLA School of Medicine and remains on the UCLA Ronald Regan Medical Center Staff.

From 1980–1997, Gale was Chairman of the Scientific Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), 1989–2003 he chaired the Scientific Advisory Board of the Center for Advanced Studies in Leukemia. From 1986–1993, he was President of the Armand Hammer Center for Advanced Studies in Nuclear Energy and Health, and 1985–1990 he was the Wald Scholar in Biomedical Communications at UCLA.


Gale is currently Visiting Professor of Haematology at the Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London and Honorary Professor of Hematology at the Institute of Hematology at Peking Union Medical College. He is the Editor-in-Chief of *Leukemia*, Associate Editor of *Clinical Transplantation*, Executive Editor of *Bone Marrow Transplantation* and a reviewer for many scientific journals in hematology, oncology, immunology, transplantation, radiation biology and internal medicine. Prof. Gale is also an expert on the medical response to nuclear and radiation accidents. He is also executive director of clinical research and development at Celgene Corp and an honorary member of the Russian and Chinese Academies of Medical Science.

Gale has published 950 scientific articles and 25 books on medical topics, nuclear energy and weapons and politics of US-Russian relations with articles for the *New York Times*, *Los Angeles Times*, *Washington Post*, *USA Today*, *Der Spiegel*, the *Wall Street Journal* and others. Dr Gale has also written popular books on Chernobyl and US nuclear energy policy and screenplays for and/or appeared in several movies and received an Emmy award. His latest book "Radiation: What it is, what you need to know" was published in 2013 by A. Knopf.

Awards for his scientific achievements include the Presidential Award, New York Academy of Sciences, Scientist of Distinction Award, Weizmann Institute of Science, Distinguished Alumni Award, Hobart College and Intra-Science Research Foundation Award. He holds honorary degrees including DSc from Albany Medical College, LHD from Hobart College and DPS from MacMurray College. He is married with 6 children and lives in Los Angeles, Montana and New York.

Hagop Kantarjian

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA



Primary Appointments:

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Vice President for Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX

Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Samsung Distinguished University Chair in Cancer Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training:

Degree-Granting Education

1983 The University of Texas MD Anderson Cancer Center, Houston, TX, Medical Oncology Subspecialty, Hematology/Oncology

1981 American University of Beirut, Beirut, Lebanon, Internal Medicine, Internal Medicine

1979 American University of Beirut, Beirut, Lebanon, MD, Medicine

1975 American University of Beirut, Beirut, Lebanon, BS, Science

1972 American University of Beirut, Beirut, Lebanon, Baccalaureate

Board Certifications:

1990 American Board of Hematology Certification

1985 American Board of Medical Oncology Certification

1983 American Board of Internal Medicine Certification

Honors and Awards:

2012 37th Jeffrey A Gottlieb Memorial Award

2010 Ben Qurrah Award

2009–2010 Best Doctors in America 2009-2010, Best Doctors

2008 The Division of Cancer Medicine, MD Anderson Cancer Center "John Mendelsohn Lifetime Scientific Achievement Award", MD Anderson Cancer Center

2008 The Division of Cancer Medicine, MD Anderson Cancer Center "Waun Ki Hong Award for Excellence in Team Science", MD Anderson Cancer Center

2005 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical

2004 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical

2003 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical

1999 Faculty Achievement Award for Clinical Research, UT M.D. Anderson Cancer Center

1998–2015 Kelcie Margaret Kana Research Chair, UT M.D. Anderson Cancer Center

1997 First Emil J Freireich Award for Outstanding Clinical Research, UT M.D. Anderson Cancer Center

1997 Outstanding Service to Mankind Award, Leukemia Society of America

1989–1994 Scholar, Leukemia Society of America

1985–1987 Special Fellow, Leukemia Society of America

1984 Fellow, Leukemia Society of America

1983 Fellow Research Award, UT M.D. Anderson Cancer Center

1982 Fellow Research Award, UT M.D. Anderson Cancer Center

1979 Alpha Omega Alpha Honor Medical Society, American University of Beirut Chapter, Beirut, Lebanon

1979 Penrose Award

1976 Lange Award

Professional Memberships:

1990–present American Association for Cancer Research

1991–present American Association for the Advancement of Sciences

1985–present American Medical Association

1995–present American Society for Clinical Oncology

1992–present American Society for Hematology

2004 Association of American Physicians

2010-present Member of the Nominating Committee, International Association for Comparative Research on Leukemia and Related Diseases, Mannheim, Germany

Rüdiger Hehlman

Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Heidelberg, Germany



Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg. Prof. Hehlmann is past Chief of Medicine at Mannheim, past President of the German Society of Hematology and Oncology, past Dean of his faculty and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is founder and chair of the German CML-Study Group, of the German

Competence Network on acute and chronic leukemias and of the European LeukemiaNet. He is honorary member of the Polish and German Societies for Hematology and honorary doctor of the University Uppsala, Sweden. He has received various awards for leukemia research and interdisciplinary cooperation. His research interests focus on leukemia, in particular CML, on mechanisms of leukemogenesis and on progression to blast crisis

Eliezer Rachmilewitz

Hematology Department, E. Wolfson Medical Center, Holon, Israel



Prof. Eliezer Rachmilewitz was born in Jerusalem. His father, Prof. Moshe Rachmilewitz, was one of the founders of modern medicine in the State of Israel.

Prof. Rachmilewitz received all his medical education in Israel and was the Head of the Hematology department in Hadassah Hospital in Jerusalem for 20 years. From 2000 to 2012, he was the Head of the Hematology department in Wolfson Hospital in Holon.

He is continuing to work as a consultant at the Wolfson

Hospital and at the Assuta Medical Center. He is also an Adjunct Professor of Medicine at New York Cornell University Presbyterian Hospital.

In 2013, he was appointed as the Head of the Medical Policy Division in the Israeli Medical Association.

During this period of time, Prof. Rachmilewitz was very active in the local as well as in the international medical community. His reputation all over the world brought into practice new therapeutic treatments to the State of Israel. Numerous patients from all over Israel and neighboring countries seeking advanced medical care have sought his consultation.

Prof. Rachmilewitz has excelled not only in patient care but has also matured a new generation of young hematologists who are at the forefront of the hematological community in nearly every hospital in Israel and abroad, from the Palestinian Authority to Ethiopia and in the United States.

His main area of research evolves around the pathophysiology of thalassemia, a disease which is highly prevalent in the Middle East and South East Asia. He and his colleagues described for the first time the presence of non transferrin bound iron (NTBI) in thalassemia which is recognized as a catalyst in the formation of oxygen free radicals and generating increased oxidative stress. He initiated the first study that showed low hepcidin levels in thalassemic mice that explained their increased iron absorption. He is considered one of the world experts in this disease and is invited all over the world to present the results of his work. In September 2005 he published a progress report on thalassemia in the *New England Journal of Medicine*, and recently on "How I Treat Thalassemia" in *Blood*. Another area that he was one of the first to explore is Hypercoagulable State in Hemoglobinopathies. His first review on this topic was published in *Blood* together with his late colleague Dr. Amiram Eldor in 2002! Recently, he has been involved in the study of multiple asymptomatic ischemic lesions in the brain of patients with thalassemia.

As an extension of studies in thalassemia, he recently became interested in the role of oxidative stress in congenital and acquired hemolytic anemias and particularly in iron overload in Myelodysplastic Syndrome (MDS), which is a relatively new area. One of his recent reviews on the impact of iron overload in low risk myelodysplastic syndrome was published in *Blood*.

Consequently, he is studying how the potential risks of oxidative damage on transformation to Leukemia and whether it can be prevented by iron chelators and/or antioxidants. One of his most recent studies is to measure iron deposition by T2* MRI in patients undergoing dialysis who receive a lot of iron, which is deposited in major organs. A review on this subject has appeared in *Nephrology, Dialysis and Transplantation*.

He is one of the most prominent physicians in Israel and one of the 3 official physicians of the Prime Minister.

He was a host of a popular weekly television program on Health issues, where he interviewed experts from all fields of medicine for more than 10 years.

Recently, he is a co-chairman of an international meeting on controversies in Hematology. The first meeting was in Rome in 2010, the second was in Barcelona in 2012, and the 3rd one took place in Istanbul in 2014.

He is married for the second time to Tova, who is an artist, a father of 3 children and 11 grand-children.

Kostas Stamatopoulos

Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece



Kostas Stamatopoulos is the Director of the Institute of Applied Biosciences at CERTH, the Center for Research and Technology Hellas, in Thessaloniki, Greece. He also holds the positions of Visiting Professor in Lymphoid Tumor Biology at Uppsala University, Uppsala Sweden; and, Research Collaborator of the Hematology Department and HCT Unit at the G. Papanicolaou Hospital, Thessaloniki, Greece. Dr. Stamatopoulos has been involved in CLL and lymphoma research

since 1994 and has published extensively about the immunobiology of CLL and other lymphomas. He is Board member of ERIC, the European Research Initiative on CLL, founding member of the IMGT CLL-DB initiative and the IgCLL group, both operating under the auspices of ERIC. His current research interests include: immunogenetics of human lymphoid malignancies; cell signaling; genetic diagnostics; precision medicine in cancer; and, patient empowerment in care.

Alan K Burnett

Former Professor of Haematology, Cardiff University, United Kingdom



Dr Alan Burnett was trained at Glasgow University in the UK. He did postgraduate research in the Ben May Laboratory for Cancer Research, University of Chicago, IL, USA, and returned to Glasgow, where he established the Stem Cell Programme, including the first CR1 autografts in acute myeloid leukaemia (AML). He was appointed chair of the Medical Research Council (MRC) Adult Leukaemia Working Party in 1989 and has acted as a coordinator of the MRC AML 10, 11, 12, 14, 15, 16,

and 17 trials. He was Professor and head of the Department of Haematology at the University of Wales College of Medicine (now Cardiff University) in 1992–2014. In 2002, the National Cancer Research Institute was established in the UK and Dr Burnett was appointed chair of its Haematological Oncology Study Group.

Dr Burnett's main research interest is the development of treatments for AML. He has published more than 300 papers and served on numerous advisory committees, and is past president of the British Society for Haematology and chair of the UK National Training Programme. He was elected as a Fellow of the Academy of Medical Sciences in 2002, was awarded the Gold Medal of the British Society for Haematology in 2004, was appointed as an MBE in the Queen's Birthday Honours for services to medicine in 2008, and received the Ham-Wasserman Lecture award from the American Society of Hematology in 2012. He is currently Global Lead for Myeloid Diseases for CTI Biopharma.

Download English Version:

<https://daneshyari.com/en/article/5527940>

Download Persian Version:

<https://daneshyari.com/article/5527940>

[Daneshyari.com](https://daneshyari.com)